The latest onvansertib data, and an abrupt CEO departure, spook investors.
ApexOnco Front Page
Recent articles
BioNTech will test the bispecific in two new lung indications.
Three private biotechs enter clinical trials, one targeting KRAS.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
$650m buys the group rights to RemeGen’s RC148.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
